BCM-95® (CURCUGREEN®), 07 Aug 2021
Dhaneshwar Shep, Chitra Khanwelkar, Prakashchandra Gade, Satyanand Karad,
Background: To compare the efficacy and safety of combination of curcuminoid complex and diclofenac vs diclofenac alone in the treatment of knee osteoarthritis (OA).
Methods: In this randomized trial, 140 patients of knee OA received either curcuminoid complex 500mg (BCM-95) with diclofenac 50mg 2 times daily or diclofenac 50mg alone 2 times daily for 28 days. Patients were assessed at baseline, day 14 and day 28. Primary efficacy measures were Knee injury and OA outcome score (KOOS) subscale at day 14 and day 28. Anti-ulcer effect and patient-physician’s global assessment of therapy at day 28 were included as secondary endpoints. Safety after treatment was evaluated by recording adverse events and laboratory investigations.
Results: Both treatment groups showed improvement in primary endpoints at each evaluation visit. Patients receiving curcuminoid complex plus diclofenac showed significantly superior improvement in KOOS subscales, viz. pain and quality of life at each study visit (P<.001) when compared to diclofenac. Less number of patients required rescue analgesics in curcuminoid complex plus diclofenac group (3%) compared to diclofenac group (17%). The number of patients who required histamine 2 (H2) blockers was significantly less in curcuminoid complex plus diclofenac group compared to diclofenac group (6% vs 28%, respectively; P<.001). Adverse effects were significantly less in curcuminoid complex plus diclofenac group (13% vs 38% in diclofenac group; P<.001). Patient’s and physician’s global assessment of therapy favored curcuminoid complex plus diclofenac than diclofenac.
Conclusion: Combination of curcuminoid complex and diclofenac showed a greater improvement in pain and functional capacity with better tolerability and could be a better alternative treatment option in symptomatic management of knee OA.
Trial Registration: ISRCTN, ISRCTN10074826